Clinical Trials

Beyond First Line Therapy

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

LEARN MORE

Beyond First Line Therapy

Phase IIb trial of pemigatinib in combination with atezolizumab and bevacizumab for treatment of advanced cholangiocarcinoma with FGFR2 fusion

LEARN MORE

Beyond First Line Therapy

Alliance EAY191-A6: A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations

LEARN MORE

First Line Therapy

FIRST-308

LEARN MORE

Targeted Therapy

phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ)  

LEARN MORE

Beyond First Line Therapy

A Study to Evaluate KIN-3248 (study drug) in Patients with Advanced Tumors Who Have FGFR2 and//or FGFR3 Gene Alterations

LEARN MORE

Targeted Therapy

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

LEARN MORE

Chemotherapy

ZW25-201: A Phase 2 Study of Zanidatamab (ZW25; bispecific antibody) Plus First-line Chemotherapy in HER2-Expressing Cancers, Including Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, and Colorectal Cancer

LEARN MORE

Beyond First Line Therapy

Safety and Tolerability of TNG908 in Patients with MTAP-deleted Solid Tumors

LEARN MORE

Targeted Therapy

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

LEARN MORE

Beyond First Line Therapy

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

LEARN MORE

Beyond First Line Therapy

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

LEARN MORE